Bend Research and Pfizer Offer Proprietary Technology to Help Solve Drug-Discovery Challenges



    
    New Partners Invited To Use Spray-Dried Dispersion (SDD) Technology To
    Overcome Problems of Low Solubility
    

    BEND, Ore., Aug. 8 /CNW/ -- Bend Research Inc. today announced a new
initiative to make available Pfizer's drug-delivery technology for improving
the clinical value of experimental compounds.
    The search for new medicines is made more difficult because many
potentially valuable compounds have low solubility and low bioavailability --
they are not easily absorbed or metabolized by the human body.
    To overcome these challenges, Bend Research and Pfizer jointly developed
the new, proprietary drug-delivery technology relying on spray-dried
dispersions (SDDs). The SDD technology has been successfully applied to more
than 200 Pfizer compounds with low aqueous solubility.
    Further, improved oral bioavailability significantly above that of
crystalline drug has been demonstrated in 17 clinical trials conducted by
Pfizer, including one Phase III trial.
    "Pfizer has always understood the value of partnering in order to
overcome the highly complex scientific challenges of drug discovery," said
John L. LaMattina, president of Pfizer Research & Development. "This new
initiative shows how we can share scientific expertise to help discover new
medicines for patients in need."
    "The SDD technology provides a significant opportunity to advance
insoluble compounds with low bioavailability," said Marshall Crew, vice
president of Bend Research. "This technology is broadly applicable to
insoluble compounds and is compatible with conventional solid dosage forms.
Bend Research looks forward to establishing new collaborations and driving
forward to new pharmaceutical products."
    Under this new initiative, Bend Research will work with research
organizations and universities and seek to apply Pfizer's SDD technology to
their compounds. The aim is to improve bioavailability in short-term
feasibility studies.
    If the results are promising, the partners will have the opportunity to
negotiate license agreements with Pfizer. Bend Research is inviting
researchers to make contact and discuss the applicability of SDDs to their
low-bioavailability compounds.
    Further information about this initiative is available at the Bend
Research website:  http://www.bendresearch.com. Companies interested in the
SDD technology should contact Dr. Jeff Gautschi at Bend Research by calling
(541) 382-4100 or e-mail drugsolubility@bendres.com. Media contacts should be
directed to Ann Malkin, Director of Communications at Bend Research, at (541)
382-4100 or malkin@bendres.com.




For further information:

For further information: Ann Malkin, Director of Communications of Bend 
Research Inc., +1-541-382-4100 Web Site: http://www.bendresearch.com

Organization Profile

BEND RESEARCH INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890